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Abstract 
The aim of this study was to compare efficacy and safety of Allium Curcuma with glibenclamide in type-2 diabetes mellitus with 
or without dyslipidemia. Thirty five patients were recruited and randomized into 2 groups for 14 weeks treatment and 
assessment. One group received study drug, three times two capsules containing 200 mg turmeric and 200 mg allium extract per 
day. The other group received 1 capsule of 5 mg glibenclamide as standard drug per day. After 14 weeks of treatment patients 
with allium curcuma treatment showed significant decreased in fasting blood glucose (192.76 versus 141.71 mg/dL) and 2 hours 
post-prandial blood glucose (295.35 versus 204.35 mg/dL). HbA1C level was also significantly decreased (10.41 versus8.09). No 
difference was found in blood pressure, hematology profile, liver and kidney function of both groups. In conclusion, allium 
curcuma has potential to be used as antidiabetic agent. 
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1. Introduction 
Globally, there is a growing prevalence of type-2 diabetes mellitus. WHO estimates that more than 180 million 
people worldwide have impaired glucose tolerance. It is predicted that the number of worldwide diabetes cases 
might increase from 171 million in 2000 to 366 million in 20301. The prevalence of diabetes mellitus in adults 
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worldwide was estimated to be 5.4% in 2025. The major increase will be in the developing countries (170% 
increase) while developed countries the increase will be 42%. Hence, it was predicted that by the year 2025, 75% of 
diabetes population reside in the developing countries2. 
Many herbal compounds have been used throughout the world for diabetes. Among others, turmeric (Curcuma 
longa L.) and garlic (Allium sativum L.) have been shown to have hypoglycemic action and therefore both are used 
for diabetes treatment3–6. A. sativum L., commonly known as garlic, has been used for medicinal purpose. When 
garlic cloves are crushed or disrupted, allinase enzyme which present in garlic (A. sativum) will act on alliin to 
produce allicin, the principal bioactive compound in garlic3,7. Turmeric, the rhizome of Curcuma longa, is also spice 
and medicinal plant used in some Asian countries. Curcuminoids are the main component in Curcuma species 
responsible for their major biological effects. Curcumin, predominantly contained in curcuminoids, has a wide range 
of pharmacological effects including reduction of bloodcholesterol and glucose levels, and other medicinal 
effects4,6,8. 
Innovation in antidiabetic agents, oral anti hyperglycaemic agents as well as insulin preparation, developed 
robustly nowadays. However, the “back to nature” (herbal) medicines are frequently considered to be less toxic than 
the synthetic drugs since they have commonly few adverse reactions. Combination of extract garlic and turmeric 
(Allium Curcuma) has been proven pre-clinically9 and clinically10 as antidiabetic agent. Our study on animal9 even 
showed that combination of both substances gives synergistic effect compared to their individual usage. Antidiabetic 
dose ranging clinical study of Allium Curcuma has been done previously and resulted the optimum dose of Allium 
Curcuma 2.4 g10. Here we conduct a study to compare efficacy and safety of Allium Curcuma with oral 
antihyperglycaemic agent Glibenclamide in type-2 diabetes mellitus patients, with or without dyslipidemia. 
 
Nomenclature 
WHO  World Health Organization 
HSH  HasanSadikin Hospital 
LDL  Low Density Lipoprotein 
BMI  Body Mass Index 
AST  Aspartate Transaminase 
ALT  Alanin Transaminase 
ECG  Electrocardiogram 
HDL  High Density Lipoprotein 
PT  Prothrombin Time 
APTT  Activated Partial Thromboplastin Time 
INR  International Normalized Ratio 
2HPP  2 Hours Post-Prandial 
AC group  Allium Curcuma Group 
Hb1AC  Glycosylated hemoglobin 
DM  Diabetes Mellitus 
PPAR-γ  Peroxisome Proliferator-Activated Receptor-γ 
ACE  Angiotensin Converting Enzyme 
FBG  Fasting Blood Glucose 
2HPP BG 2 Hours Post-Prandial Blood Glucose 
2. Experiments 
This is a double blind, parallel, randomized control trial conducted in 14 weeks. The study protocol was approved 
by Ethics Committee on Research in Human, Hasan Sadikin Hospital (HSH), Bandung, Indonesia. Written informed 
consent was obtained from each patient before any procedure was performed. This clinical study was conducted 
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according to Good Clinical Practice Procedure and in accordance with precepts established by the Declaration of 
Helsinki in 1974. 
2.1. Subjects 
Male or female patients with type-2 diabetes mellitus aged more than 35 years old, who had random blood 
glucose level ≥200 mg/dL, fasting blood glucose level ≥126 mg/dL with or without dyslipidemia (total cholesterol 
>200 mg/dL and LDL >130 mg/dL) were recruited.  
Table 1. Baseline data of the patients (n=29) 
 Parameters AC Glibenclamide p value 
Demography 
Age (years) 53.12 ± 2.11 52.83 ± 2.26 0.929 
Weight (kg) 62.53 ± 2.46 57.21 ± 2.88 0.173 
BMI (kg/m2) 25.80 ± 1.05 24.70 ± 1.43 0.53 
Blood 
pressure 
Systole (mmHg) 126.56 ± 3.19 124.25 ± 5.54 0.704 
Diastole (mmHg) 81.25 ± 1.25 81.08 ± 2.77 0.953 
Diabetic 
parameters 
Fasting glucose (mg/dL) 192.76 ± 14.59 250.33 ± 14.55 0.012* 
2 hours PP glucose (mg/dL) 295.35 ± 18.58 374.83 ± 28.63 0.022* 
HbA1C (%) 10.41 ± 0.64 11.86 ± 0.53 0.104 
Insulin (pmol/L) 56.89 ± 14.40 59.98 ± 17.83 0.894 
Haematology 
Haemoglobin (g/dL) 14.53 ± 0.44 14.52 ± 0.48 0.990 
Leukocyte (103/mm3) 8.07 ± 0.72 7.81 ± 0.50 0.771 
Thrombocyte (103/mm3) 271.73 ± 21.45 267.33 ± 14.19 0.864 
Haematocrite (%) 42.92 ± 1.19 41.92 ± 1.19 0.558 
Blood 
coagulation 
parameters 
PT (second) 12.66 ± 0.16 12.73 ± 0.18 0.785 
APTT (second) 29.17 ± 0.99 29.38 ± 0.72 0.857 
INR 0.94 ± 0.01 0.94 ± 0.01 0.902 
Lipid profile 
Total cholesterol (mg/dL) 238.06 ± 8.25 235.67 ± 7.66 0.84 
HDL (mg/dL) 46.35 ± 2.23 44.25 ± 2.82 0.559 
LDL (mg/dL) 156.59 ± 8.66 150.45 ± 7.33 0.623 
Triglyceride (mg/dL) 162.82 ± 13.74 202.08 ± 33.35 0.294 
Liver 
function 
AST (U/L) 24.77 ± 2.57 23.83 ± 3.17 0.819 
ALT (U/L) 22.92 ± 3.28 27.42 ± 3.10 0.332 
Kidney 
function 
Ureum (mg/dL) 23.46 ± 1.77 27.08 ± 1.57 0.168 
Creatinine (mg/dL) 0.84 ± 0.05 0.78 ± 0.08 0.506 
Note: All baseline data was measured on week 0; except blood coagulation parameters, liver function, kidney function, insulin and HbA1C were 
on week 2. * statistically significant difference (p<0.05) 
The recruited patients must have never received oral hypoglycaemic agent or insulin prior this study and were 
willing to sign informed consent. Patients with type-1 diabetes mellitus or patients who previously received 
antidiabetic therapy, steroid or oral contraception; patients with renal and liver failure; patients with ketoacidosis 
complication, diabetic ulcer or gangrene; pregnant and lactating women, were excluded. Patients’ baseline 
characteristic was shown in Table 1. 
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2.2. Preparation of study drugs 
Study drug (Allium Curcuma) was 400 mg capsule contains 200 mg of turmericethanolic extract and 200 mg 
ofgarlicaqueous extract. Standard drug was 5 mg Glibenclamide (produced by Indofarma, Pte. Ltd., Indonesia). 
2.3. Study Design 
Patients were assigned in a run-in phase for two weeks before the treatment. During run-in phase they were 
regularly doing diet and exercise. Demographic data, daily habits, such as cigarette smoking and alcohol 
consumption, medical history, and body mass index (BMI) were recorded at the first visit. After the run-in phase, 
patients were screened again for the blood glucose level and lipid profiles based on the inclusion criteria. Patients 
who failed to improve their blood glucose and lipid profile were divided subject into two groups, i.e. AC group and 
glibenclamide group. AC group received2.4 g Allium Curcumacapsules administered astwo times three capsules  
per day (morning and evening) after meal. Glibenclamide group also received two times three capsules per 
day,however at morning after breakfast they consumed one capsule contain 5 mgGlibenclamide plus two capsules 
contains placebo and at evening after dinner they consumed three placebo capsules. Subjects were still encouraged 
to continuediet and exercise. 
Subjects were evaluated every two weeks for 12 weeks. Anamnesis and physical examination were done every 
visit including signs and symptoms, adverse events, any concomitant medication, and clinical improvement. Fasting 
blood glucose, 2 hours post-prandial (2HPP) blood glucose, lipid profile examination were done every two weeks 
from week-0 to week-14. HbA1C, fasting insulin, liver function, renal function, complete hematology, urine, and 
heart function examination were done in week-2 and week-14. Complete examinations were not done on week-0 
because patients still had possibility to be excluded if blood glucose level became normal after 2 weeks run-in 
phase. Safety and quality of life evaluation were done by anamnesis on every visit. Study flowchart is shown in Fig. 
1. 
2.4. Measurement of blood glucose, lipid profile, and other haematological parameters 
These following measurements were done during each visit: fasting blood glucose level, 2 hours post-prandial 
glucose level, HbA1C, fasting insulin level, lipid profile (total cholesterol, HDL, LDL and triglyceride); hematology 
parameters including hematocrit, hemoglobin, leukocyte and thrombocyte; PT, APTT and INR; renal function 
(ureum and creatinine); heart function (ECG); liver function (AST and ALT); symptoms and signs, adverse events, 
and physical examinations (body mass index and blood pressure). All clinical tests were done in Hasan Sadikin 
Hospital. 
2.5. Statistical Method and Data Analysis 
Data results were analyzed by general linear model repeated measure method to determine the differences in 
intra-group and intergroup from week 0 to week 14. Baseline characteristics were evaluated by independent t-test 
and proportion test was analyzed by chi square method. 
Blood glucose profile and body mass index from week to week were analyzed per-protocol in order to reveal 
maximal therapeutic efficacy whereas for parameter analysis, supporting laboratory examination and adverse events 
were analyzed per intent-to-treat to get complete information. 
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Not met criteria 
Met criteria 
DM naive patients at Hasan Sadikin Hospital, Bandung 
Inclusion criteria 
Exclusion criteria 
Excluded 
Excluded 
Group I 
Trial drug: combination of extract Allium 
Curcuma, dose 2.4 g/day
12 weeks observation 
¾ Routine tests every 2 weeks : physical examination (weight, height, blood pressure, heart rate, 
respiratory rate) and laboratory tests (lipid profile, blood glucose, urine screening/routine test) 
¾ Tests at beginning and end of trial : ECG, HbA1C, insulin, liver function (AST, ALT), kidney 
function (ureum, creatinine), and hematology (Hb, hematocrit, leukocyte, thrombocyte, PT, APTT) 
¾ Tests at week 8: liver function (AST, ALT), kidney function (ureum, creatinine), and hematology 
(Hb, hematocrite, leukocyte, thrombocyte) 
Data analysis 
Statistical analysis using GLM repeated 
measure 
Grup II 
Standard drug: Glibenclamide, single 
dose 5 mg/day
2 weeks diet 
Clinical trial patients randomization 
2 HPP BG >200mg/dL and/or 
FBG >126 mg/dL 
triglyceride >200 mg/dL
FBG < 126 mg/dL 
and/or 
2 HPP BG < 200 mg/dL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1. Study flowchart, FBG: fasting blood glucose, 2HPP BG: 2 hours post-prandial blood glucose. 
3. Results and Disussion 
3.1. Demographic Characteristic of the Patients 
Thirty six type-2 diabetes mellitus patients were eligible and recruited for this study. After randomization, 17 
patients were in AC group and 12 patients in glibenclamide group. Demographic data and laboratory parameters 
(Table 1) showed a comparable profile between both groups, except fasting blood glucose and 2HPP blood glucose 
levels (p<0.05). 
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3.2. Fasting Blood Glucose and 2 Hours Post-Prandial Blood Glucose Levels  
The intra-group analysis of fasting blood glucose and 2 hours postprandial (2HPP) blood glucose levels duringthe 
studyshoweda significant decrease (p<0.05),but there was no significant difference in inter-group analysis (p=0.529) 
(Table 2, Fig. 2 and 3).  
Table 2. Fasting and 2 hour post-prandial blood glucose levels on week 0 - 14. 
Week 
Fasting Glucose Levels 
(mg/dL) 
2 HPP Blood Glucose 
(mg/dL) 
AC 
(n=17) 
Glibenclamide (n=12) 
AC 
(n=17) 
Glibenclamide (n=12) 
0 192.76 ± 14.59 250.33 ± 14.55 295.35 ± 18.58 374.83 ± 28.63 
2 157.53 ± 8.51 221.08 ± 18.03 231.29 ± 12.17 334.75 ± 27.53 
4 154.41 ± 9.04 133.25 ± 8.69 241.59 ± 15.40 204.75 ± 18.10 
6 148.88 ± 10.52 130.33 ± 11.86 228.41 ± 14.82 212.25 ± 18.08 
8 140.47 ± 11.69 121.67 ± 6.13 214.59 ± 12.99 210.67 ± 18.43 
10 141.53 ± 12.19 128.92 ± 9.92 201.06 ± 18.14 208.45 ± 16.30 
12 139.65 ± 12.01 143.75 ± 17.47 212.29 ± 14.47 246.60 ± 22.01 
14 141.71 ± 9.67 154.50 ± 24.06 204.35 ± 11.11 228.83 ± 21.71 
Intra-group  
p value 
0.028* 0.003* 0.019* 0.020* 
Inter-group  
p value 
0.529 0.061 
Note: * statistically significant (p<0.05) 
 
The blood glucose levels of the patients were also grouped, based on Indonesian Endocrinologist Association 
criteria, into poor, moderate, and good (Table 3). After 14 weeks treatment, percentages of patients in AC group 
with good and moderate 2HPP blood glucose profile increased from 0% of both categories to 11.8% (good) and 
17.6% (moderate). While in Glibenclamide group, these percentages were also increasing from 0% in both 
categories to 8.3% (good) and 25% (moderate). The percentage of subjects with poor postprandial glucose in week 
14 was equal in both groups, i.e. 70.6% in AC group versus 66.7% in Glibenclamide group. The percentage of 
patients in AC group with good and moderate fasting blood glucose level after 14 weeks of treatment increased from 
0% to 5.9 % in good category and from 11.8% to 17.6 % in moderate category. In Glibenclamide group, these 
percentages increased from 0% to 16.7 % in good category and from 0% to 33.3 % in moderate category. The 
percentage of subject with poor fasting blood glucose levels after 14 weeks of treatment in AC group was 76.5% and 
50% in the Glibenclamide group. Although it was observed a shift from poor 2HPP and fasting blood glucose levels 
into moderate or good categories, the differences were not statistically significant (Table 3). Therefore, AC 
treatment has shown a comparable result as Glibenclamide. 
As shown in Figure 2 and 3, the decrease of fasting and 2HPP blood glucose levels in AC and Glibenclamide 
groups showed similar trend at week 4-14 of treatment. All sulphonylureas are well absorbed and their peak plasma 
concentration is reached in 2-4 hours11. On the contrary, garlic and turmeric preparation decreases blood glucose 
slowly by increasing sensitivity to insulin12–14. The mechanism of turmeric as antidiabetic is through PPAR-γ 
(peroxisome proliferator-activated receptor-γ) activation. Activated PPAR-γ regulates transcription of responsive 
gene to insulin that involve in producing, transporting and using glucose with the result are lower blood glucose and 
hyperinsulinemia15. 
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Table 3. Patients proportion based on blood glucose control criteria. 
Blood Glucose Criteria 
Week 0 Week 14 
AC 
(n=12) 
Glibenclamide 
(n=12) 
AC 
(n=17) 
Glibenclamide 
(n=12) 
2 hour postprandial 
(mg/dL)  
Good (110-159) 0 (0%) 0 (0%) 2 (11.8%) 1 (8.3%) 
Moderate (160-199) 0 (0%) 0 (0%) 3 (17.6%) 3 (25%) 
Bad (≥200) 17 (100%) 12 (100%) 12 (70.6%) 8 (66.7%) 
Inter-group p value  NA 0.870 
Fasting (mg/dL) 
Good (80-109) 0 (0%) 0 (0%) 1 (5.9%) 2 (16.7%) 
Moderate (110-139) 2 (11.8%) 0 (0%) 3 (17.6%) 4 (33.3%) 
Bad (≥140) 15 (88.2%) 12 (100%) 13 (76.5%) 6 (50%) 
Inter-group p value  0.335 0.323 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Fasting blood glucose profile during study. 
Insulin is a regulator of glucose level. Garlic could reduce blood glucose by two mechanisms, i.e. by promoting 
insulin secretion and by increasing sensitivity to insulin14. As cited El-Demerdash reported16, garlic can combine 
with cysteine-like compound and enhance serum insulin. Garlic can also increase insulin secretion from pancreatic 
beta cells or release the bound-insulin16. Despite the insulin secretagogue property of garlic, in this study the fasting 
insulin level was reduced in AC group. Fasting insulin level has been considered as one of insulin resistance 
surrogate markers17. Insulin sensitivity and insulin secretion are inversely related, therefore when insulin sensitivity 
is increased then insulin secretion is reduced18. Thus in this study, decrease of fasting insulin level in AC group 
indicated that Allium Curcuma might play a role in lowering insulin resistance.  
3.3. HbA1C and Insulin 
HbA1C and insulin examinations were done before and week 2 and week 14 after treatment. There was a 
decrease in insulin level at week 14 compared to week 2 in AC and Glibenclamide groups, but the decrease in AC 
group was greater than in Glibenclamide group (9.26 pmol/L versus 0.304 pmol/L) (Table 4).  
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Fig. 3.Two hours post-prandial blood glucose profile during study. 
Table 4. HbA1C and insulin levels on week 2 and week 14 
 Week 2 X ± SEM 
Week 14 
X ± SEM 
Delta 
X ± SEM 
Intra-group 
p value 
Inter-
group p 
value 
HbA1c (%)      
AC  (n=15) 10.41 ± 0.64 8.09 ± 0.37 -2.33 ± 0.47 0.000* 
0.368 
Glibenclamide (n=12) 11.86 ± 0.53 7.86 ± 0.45 -4.00 ± 0.36 0.000* 
Insulin (pmol/L)      
AC  (n=15) 56.89 ± 14.40 47.64 ± 12.34 -9.26 ± 7.68 0.153 
0.711 
Glibenclamide (n=12) 59.98 ± 17.83 59.68 ± 14.05 -0.30 ± 10.13 0.675 
Note: * statistically significant difference (p<0.050) 
 
We grouped the subjects based on criteria for HbA1C control for DM treatment into poor, moderate, and good 
categories. It was found that there was no significant difference between both treatment groups (p=0.368) (Table 5), 
although the decrease of HbA1C level in both AC and Glibenclamide groups before and week 14 after treatment 
were significant (p=0.000) (Table 4). 
Allium and curcumin are also known to have antiglycation effect that prevents the progressive of type-2 DM 
complication14,18. Glycosylated hemoglobin (HbA1c) was measured in this study as a marker of long-term glycemic 
control and long-term complications of diabetes17and showed significant decreases in both AC and Glibenclamide 
groups. The HbA1c decrease did not significantly differ between two groups indicating a comparable glycemic 
control of Allium Curcuma and standard drug, Glibenclamide. 
3.4. Body Mass Index (BMI) 
Body mass index (BMI) is an indicator to determine overweight or obesity level on adults. To prevent chronic 
complications of DM, patients have also to control their nutrition status as depicted by the BMI.The body weight 
(Table 7) and BMI status (Table 6 and Figure 4) ofpatients in Glibenclamide group showed significant increases 
during the study (p=0.015 and p=0.034, respectively). On contrary, body weight and BMI decreased was observed 
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in AC group although the decrease of BMI was not statistically significant (p=0.068) while the body weight 
decrease was significant (p=0.006).  
Table 5. Patient proportion based on HbA1C control criteria 
 Criteria 
Week 0 Week 14 
AC Glibenclamide AC Glibenclamide 
HbA1C 
Good (< 6.5%) 0 (0%) 0 (0%) 0 (0 %) 3 (25%) 
Moderate (6.5-8%) 3 (20%) 0 (0%) 8 (53.3 %) 5 (41.7%) 
Bad (>8%) 12 (80%) 12 (100%) 7 (46.7%) 4 (33.3%) 
Inter-group p value 0.156 0.121 
Table 6. Body mass index profile  
Week 
BMI (kg/m2) 
AC (n=17) Glibenclamide (n=12) 
0 25.80 ± 1.05 24.70 ± 1.43 
2 25.39 ± 1.01 24.65 ± 1.38 
4 25.55 ± 1.01 25.19 ± 1.43 
6 25.48 ± 1.05 25.46 ± 1.47 
8 25.18 ± 0.95 25.52 ± 1.47 
10 25.43 ± 1.03 25.48 ± 1.41 
12 25.27 ± 1.00 25.60 ± 1.37 
14 24.77 ± 1.00 25.54 ± 1.40 
Intra-group p value  0.068 0.034* 
Inter-group p value 0.705 
Note: * statistically significant difference 
Increased body weight and BMI in Glibenclamide group was possibly because increase of insulin secretion by 
Glibenclamide. Higher insulin level will increase glucose transfer to cells and prevent lipolysis which leads to more 
body fat and eventually higher body weight that in turn is related to insulin resistance. Insulin sensitivity will 
decrease 30-40% in people with 35-40% increase of body weight. Obesity will also increase the risk of 
cardiovascular complication. Interestingly, Allium Curcuma administration did not increase body weight. Even 
Longquan Yu and Hiramitsu Suzuki reported that feeding mice with food containing 1% allium or curcuma for 90 
days will lower body weight compared to baseline data19. Curcumin supplementation could increase fatty acid 
oxidation and decrease fatty acid esterification which led to adipose tissue catabolism20. Loss of body weight would 
in turn decrease the insulin resistance 
3.5. Hematology Parameters 
Blood profiles in both AC and Glibenclamide group were in normal range. Glibenclamide nor extract combination 
of AC did not alter hematology profile. The ALT and AST in AC group showed a significant decreased (p=0.048 
andp=0.007, respectively), while it was observed slight increase of ALT and AST levels in Glibenclamide group 
(p=0.091 and p=0.228, respectively). The levels of ureum and creatinin showed slight increases but there were no 
significant differences between both AC and Glibenclamide group (p>0.05) and there were still in normal limits 
(Table 7). 
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Fig. 4. BMI profile during study. 
3.6. Other Supporting Parameters   
Lipid profiles of patients in AC group showed a significant total cholesterol decrease (p=0.045) and also slight 
decreases of triglyceride and LDL levels, while in Glibenclamide group total cholesterol and LDL levels decreased 
significantly (p<0.001). The HDL levels in both groups showed no changes. Observation on blood pressure showed 
that there were no significant changes on blood pressure profile of AC or Glibenclamide treatment groups during the 
study (Table 7). 
Table 7. Other supporting parameters among ITT patients 
Parameters Treatment Group n Before treatment After treatment pa pb 
Demography                     
Weight (kg) AC 20 61.85 ± 2.12 60.33 ± 1.99 0,008* 0.269 
  Glibenclamide 16 56.59 ± 2.50 58.38 ± 2.59 0.015*   
Systole (mmHg) AC 18 128.06 ± 3.86 126.06 ± 3.43 0.545 0.224 
  Glibenclamide 16 120.69 ± 4.50 121.56 ± 3.91 0.855   
Diastole (mmHg) AC 18 81.67 ± 1.21 81.06 ± 2.12 0.77 0.173 
  Glibenclamide 16 78.94 ± 2.34 77.75 ± 1.75 0.628   
Hematology           
Hemoglobin (g/dL) AC 13 14.26 ± 0.48 13.48 ± 0.46 0.109 0.614 
  Glibenclamide 15 14.35 ± 0.40 13.99 ± 0.58 0.509   
Leukocyte (/mm3) AC 13 8.06 ± 0.66 7.91 ± 0.50 0.698 0.781 
  Glibenclamide 15 7.75 ± 0.44 7.79 ± 0.68 0.916   
Thrombocyte (/mm3) AC 12 277.83 ± 20.51 262.83 ± 12.56 0.213 0.808 
  Glibenclamide 15 270.20 ± 12.16 259.93 ± 19.31 0.513   
Hematocrit (%) AC 13 42.62 ± 1.14 40.62 ± 1.20 0.101 0.991 
  Glibenclamide 15 41.73 ± 0.97 41.53 ± 1.78 0.901   
Lipid Profile            
Total Cholesterol 
(mg/dL) AC 20 240.15 ± 8.01 226.65 ± 7.95 0.045* 0.004 
  Glibenclamide 16 234.38 ± 6.16 175.63 ± 6.45 0.000*   
HDL (mg/dL) AC 20 48.15 ± 2.45 48.35 ± 2.37 0.94 0.104 
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Parameters Treatment Group n Before treatment After treatment pa pb 
  Glibenclamide 16 43.75 ± 2.36 43.00 ± 2.37 0.756   
LDL (mg/dL) AC 20 151.70 ± 9.31 148.30 ± 6.71 0.687 0.011 
  Glibenclamide 15 152.07 ± 5.87 96.60 ± 8.31 0.000*   
Triglyceride (mg/dL) AC 20 179.10 ± 21.67 149.75 ± 12.00 0.195 0.3 
  Glibenclamide 16 209.56 ± 30.64 186.25 ± 40.11 0.508   
Liver Function                     
AST (U/L) AC  14 24.43 ± 2.40 18.43 ± 1.22 0.007* 0.128 
  Glibenclamide 16 23.06 ± 2.55 31.88 ± 5.20 0.228  
ALT (U/L) AC  14 22.50 ± 3.07 16.50 ± 1.56 0.048* 0.045* 
  Glibenclamide 16 27.94 ± 3.04 43.38 ± 12.33 0.091   
Kidney Function           
Ureum (mg/dL) AC 14 24.79 ± 2.10 27.71 ± 1.82 0.218 0.503 
  Glibenclamide 16 26.56 ± 1.39 28.56 ± 1.73 0.37   
Creatinine (mg/dL) AC 15 0.85 ± 0.05 0.94 ± 0.11 0.441 0.481 
  Glibenclamide 16 0.80 ± 0.06 0.86 ± 0.07 0.036*   
Clotting Blood 
Function           
PT (second) AC 9 12.66 ± 0.16 12.82 ± 0.18 0.24 0.76 
  Glibenclamide 13 12.74 ± 0.17 12.62 ± 0.16 0.577   
APTT (second) AC 9 29.17 ± 0.99 29.79 ± 0.66 0.393 0.642 
  Glibenclamide 13 29.14 ± 0.70 30.78 ± 0.87 0.077   
INR AC 9 0.94 ± 0.01 0.95 ± 0.02 0.434 0.538 
  Glibenclamide 13 0.94 ± 0.01 0.93 ± 0.01 0.65   
Note:  pa: intra-group p value;  pb:inter-group p value. Baseline data is data on week 0, except blood coagulation function values, liver function, 
insulin and HbA1C were data on week 2. *: statistically significant difference (p<0.050). The decrease of  lipid level on Glibenclamide group was 
caused by simvastatin drug used by 12 out of 16 subjects. 
3.7. Adverse Events  
Adverse events were considered to be related to Allium Curcuma or Glibenclamide when they have been 
reported elsewhere (Table 8). Seven out of 20 patients (35%) in AC group did not have any complaints at all during 
the trial. Few patients receiving AC drug complained about gastrointestinal disorders such as burn sensation on 
abdominal, gastric pain.Unpleasant breath and body odor that usually are the major complaintsof garlic consuming 
were not reported in this study. It seemed that allium’s strong scent was covered by curcuma. In contrast, 15 out of 
16 patients (93.8%)in Glibenclamide group have experienced adverse events. There were also not reported any drug 
interactions with the drugs consumed during the study by patients in AC group including analgesic (acetaminophen), 
anti-inflammation, ACE inhibitor, and vitamins. 
Lower AST and ALT values in the AC group might be due to hepatoprotector effect of Allium Curcuma. Study in 
animal showed that allicin in allium works as hepatoprotector and decrease AST and ALT levels in mice that had 
been induced by galactosamine21or by streptozotocin22. The hepatoprotector effect might also be related with 
antioxidant effect of garlic and turmeric19,23. It was reported that the S-allylcysteinsulfoxide contained in garlic 
could maintain the free radical levels16and curcumin could inhibit lipid peroxidation  in diabetic animal model18.  
The improvement on clinical symptoms in AC and Glibenclamide group was basically equal.When blood glucose 
levels were already within normal range, the diabetic classical symptoms were improved or even disappeared. Five 
subjects on AC group reported improvement of neuropathy symptoms such as paresthesia and tingling, and only 1 of 
8 patients in Glibenclamide group was reporting the improvement. Improvement of polyuria was reported by 4 of 5 
patients in AC group, and 1 of 5 patients in Glibenclamide group. 
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Table 8.  Adverse events reported during the study 
Adverse events 
AC treatment (n=20) Glibenclamide treatment (n=16) 
Grade N (%) Relationship to treatment Grade N (%) 
Relationship to 
treatment 
Gastrointestinal tract 
Constipation Mild 2(10) Not related - - - 
Nausea Mild 2(10) Not related Mild 1(6.3) Possibly related 
Diarrhea Mild 1(5) Not related Mild 1(6.3) Not related 
Burn sensation on 
abdomen Mild-moderate 2(10) Possibly related - - - 
Gastric discomfort Mild 1(5) Possibly related Mild 1(6.3) Possibly related 
Respiratory tract 
Cough Mild 2(10) Not related Mild 1(6.3) Not related 
Flu Mild 2(10) Not related Mild 1(6.3) Not related 
Allergic reactions 
Itchy Mild 2(10) Not related Mild 1(6.3) Not related 
Dispnea (asthma) Mild 1(5) Not related - - - 
Central nervous system (CNS) 
Dizziness Mild 3(15) Not related Mild-moderate 5(31.2) Possibly related 
Musculoskeletal 
Shoulder pain Mild 1(5) Not related - - - 
Tiredness Mild 1(5) Not related - - - 
Stiffness Mild 3(15) Not related - - - 
Bone/muscle pain Mild 1(5) Not related Mild-moderate 2(12.5) Possibly related 
Ocular system 
Blurred vision - - - Mild-moderate 2(12.5) Not related 
Others 
Urinary incontinence Mild 1(5) Not related - - - 
Increased creatinine Moderate 1(5) Not related - - - 
Swollen feet - - - Mild 1(6.3) Not related 
Hypoglycemia - - - Moderate 2(12.5) Related 
Palpitation - - - Mild 1(6.3) Not related 
Increased ALT - - - Moderate 2(12.5) Not related 
Notes : N = number of subjects 
 
The increasing use of herbal medicines has raised the concern about the potency of herbal-drug interactions. 
Concurrent use of herbal remedies may augment or reduce the effect of several conventional drugs. Concomitant use 
of garlic and turmeric with anticoagulant/anti-platelet agents may increase bleeding tendency24–26. Despite possible 
pharmacokinetic or pharmacodynamic interactions between Allium Curcuma and concurrent conventional drugs, 
including acetaminophen, aspirin, ACE inhibitor, theophylline, there was no observed symptom indicating drug 
interactions during this study. This suggested that the possible herbal-drug interactions of Allium Curcuma may not 
have major clinical significance, although a more detail data collection should be performed in the future to identify 
symptoms caused by toxicity or by the interactions. 
4. Conclusion 
This study demonstrated that the effect Allium Curcuma was comparable to Glibenclamide on decreasing blood 
glucose in type 2 DM patients. The administration of Allium Curcuma was well-tolerated and no drug interaction 
was reported during the trial. 
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